Driven by Curiosity. Guided by Evidence.

Dedicated to Advancing Dermatologic Care.

Dr. Jedlowski’s award-winning research has been recognized and presented at several national conferences. He has published over 30 articles in multiple high-impact journals including:

  • The Journal of the American Academy of Dermatology

  • Journal of the European Academy of Dermatology

  • The American Journal of Clinical Dermatology

  • The Australasian Journal of Dermatology

  • The Journal of Dermatology

Dr. Jedlowski’s research awards and honors include:

2023 Resident of Distinction Award

Group of five people, three women seated on a wooden bench and two men standing behind them, inside a lush, green indoor garden area, attending an award event at Maui Derm.

Doximity.com most cited clinician 

List of academic achievements with citation years from 2021 to 2025, including accolades for most cited works in 2021, 2022, 2024, and 2025, and a notable role as Clinical Trial Leader.

2023 Everett C. Fox Memorial Award 

Group of seven people standing together at a conference, smiling, wearing conference badges, against a beige wall.

2025 Tromovitch Award Nominee 

A conference room with a large presentation screen displaying a slide about pharmacovigilance and the FDA Adverse Event Reporting System, with a panel of five people sitting at a table and one man standing at a podium.

Japanese Dermatologic Association - 2022 JD Award 

Certificate awarding Patrick M. Tedlowski the JD Award from The Journal of Dermatology for most cited paper in 2022 impact factor period.

FULL PUBLICATION BIBLIOGRAPHY

  1. Jedlowski, P., Rose, A., & DuPont, J. (2026). Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System (FAERS). Australasian Journal of Dermatology, 67(1), e11–e16. https://doi.org/10.1111/ajd.70016

  2. Leibovit-Reiben, Z., Godfrey, H., Jedlowski, P., & Thiede, R. (2025). Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. Melanoma Research, 35(2), 122–129. https://doi.org/10.1097/CMR.0000000000001015

  3. Leibovit-Reiben, Z., Godfrey, H., Jedlowski, P., & Thiede, R. (2026). TNF-α Inhibitor Associated Psoriasis in Rheumatoid Arthritis and Inflammatory Bowel Disease Patients: A Disproportionality Analysis Using the FDA Adverse Event Reporting System. Journal of Cutaneous Medicine and Surgery, 30(1), 77–78. https://doi.org/10.1177/12034754251345802

  4. Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., & Thiede, R. (2025). Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology, 39(2), e153–e154. https://doi.org/10.1111/jdv.20197

  5. Jedlowski, P. M., & DuPont, J. P. (2024). Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system. Journal of the European Academy of Dermatology and Venereology, 38(5), 937–944. https://doi.org/10.1111/jdv.19703

  6. Godfrey, H., Jedlowski, P., & Thiede, R. (2024). Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System. Australasian Journal of Dermatology, 65(3), 243–253. https://doi.org/10.1111/ajd.14262

  7. Jedlowski, P. M., & Jedlowski, M. F. (2022). Topical ophthalmic beta-blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system. Australasian Journal of Dermatology, 63(2), 222–227. https://doi.org/10.1111/ajd.13828

  8. Jedlowski, P. M., Jedlowski, M. F., & Fazel, M. T. (2021). DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. American Journal of Clinical Dermatology, 22(6), 891–900. https://doi.org/10.1007/s40257-021-00625-4

  9. Jedlowski, M. F., & Jedlowski, P. M. (2021). Ulcerated and Verrucous Plaque on the Chest. Cutis, 108(2), E10–E12. https://doi.org/10.12788/cutis.0328

  10. Jedlowski, P. M., & Jedlowski, M. F. (2021). Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine. Dermatology Online Journal, 27(1).

  11. Jedlowski, P. M., Rainwater, G., & Paek, S. Y. (2020). Punctate porokeratosis-pruritic and hyperkeratotic papules on the palms and feet. Proceedings (Baylor University. Medical Center), 33(3), 415–416. https://doi.org/10.1080/08998280.2020.1755212

  12. Jedlowski, P. M., Fazel, M., Foshee, J. P., & Curiel-Lewandrowski, C. (2020). A patient with concurrent prurigo nodularis and squamous cell carcinomas of keratoacanthoma type: The role of aprepitant in diagnostic clarity. JAAD Case Reports, 6(1), 3–5. https://doi.org/10.1016/j.jdcr.2019.10.014

  13. Fazel, M., & Jedlowski, P. M. (2019). Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Reports in Immunology, 2019, 2539493. https://doi.org/10.1155/2019/2539493

  14. Jedlowski, P. M., Te, C. H., Segal, R. J., & Fazel, M. T. (2019). Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review. American Journal of Clinical Dermatology, 20(1), 97–114. https://doi.org/10.1007/s40257-018-0400-7

  15. Shi, C. X., Kortüm, K. M., Zhu, Y. X., Bruins, L. A., Jedlowski, P., Votruba, P. G., Luo, M., Stewart, R. A., Ahmann, J., Braggio, E., & Stewart, A. K. (2017). CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma. Molecular Cancer Therapeutics, 16(12), 2862–2870. https://doi.org/10.1158/1535-7163.MCT-17-0130

  16. Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C. X., Zhu, Y. X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., Stewart, R. A., Andrulis, M., Jauch, A., Hillengass, J., Goldschmidt, H., Bergsagel, P. L., Braggio, E., Stewart, A. K., & Raab, M. S. (2016). Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood, 128(9), 1226–1233. https://doi.org/10.1182/blood-2016-02-698092

  17. Kortuem, K. M., Braggio, E., Bruins, L., Barrio, S., Shi, C. S., Zhu, Y. X., Tibes, R., Viswanatha, D., Votruba, P., Ahmann, G., Fonseca, R., Jedlowski, P., Schlam, I., Kumar, S., Bergsagel, P. L., & Stewart, A. K. (2016). Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer Journal, 6(2), e397. https://doi.org/10.1038/bcj.2016.1

  18. Kortüm, K. M., Zhu, Y. X., Shi, C. X., Jedlowski, P., & Stewart, A. K. (2015). Cereblon binding molecules in multiple myeloma. Blood Reviews, 29(5), 329–334. https://doi.org/10.1016/j.blre.2015.03.003

  19. Kortüm, K. M., Langer, C., Monge, J., Bruins, L., Zhu, Y. X., Shi, C. X., Jedlowski, P., Egan, J. B., Ojha, J., Bullinger, L., Kull, M., Ahmann, G., Rasche, L., Knop, S., Fonseca, R., Einsele, H., Stewart, A. K., & Braggio, E. (2015). Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Annals of Hematology, 94(7), 1205–1211. https://doi.org/10.1007/s00277-015-2344-9

  20. Kortüm, K. M., Langer, C., Monge, J., Bruins, L., Egan, J. B., Zhu, Y. X., Shi, C. X., Jedlowski, P., Schmidt, J., Ojha, J., Bullinger, L., Liebisch, P., Kull, M., Champion, M. D., Van Wier, S., Ahmann, G., Rasche, L., Knop, S., Fonseca, R., Einsele, H., Stewart, A. K., & Braggio, E. (2015). Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3)P) in -17p high risk disease. British Journal of Haematology, 168(4), 507–510. https://doi.org/10.1111/bjh.13171

  21. Zhu, Y. X., Yin, H., Bruins, L. A., Shi, C. X., Jedlowski, P., Aziz, M., Sereduk, C., Kortuem, K. M., Schmidt, J. E., Champion, M., Braggio, E., & Keith Stewart, A. (2015). RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood, 125(3), 483–491. https://doi.org/10.1182/blood-2014-05-577130

  22. Zhu, Y. X., Braggio, E., Shi, C. X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X. B., Langlais, P., Luo, M., Jedlowski, P., LaPlant, B., Laumann, K., Fonseca, R., Bergsagel, P. L., Mikhael, J., Lacy, M., Champion, M. D., & Stewart, A. K. (2014). Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood, 124(4), 536–545. https://doi.org/10.1182/blood-2014-02-557819

  23. Jedlowski, P. M., & Jedlowski, M. F. (2022). Coronavirus disease 2019-associated immunoglobulin A vasculitis/Henoch-Schönlein purpura: A case report and review. The Journal of Dermatology, 49(3), 360–365. https://doi.org/10.1111/1346-8138.16211

  24. Jedlowski, P. M., Jedlowski, M. F., & Segal, R. J. (2021). Polydactylous Squamous Cell Carcinoma of the Nail Unit: A Structured Review of the Literature. Journal of Cutaneous Medicine and Surgery, 25(4), 418–424. https://doi.org/10.1177/1203475420977474

  25. Jedlowski, P. M., Te, C. H., Segal, R. J., & Fazel, M. T. (2017). Evaluation and Treatment of Acute and Subacute Hearing Loss: A Review of Pharmacotherapy. Pharmacotherapy, 37(10), 1295–1306. https://doi.org/10.1002/phar.2044

  26. Kortüm, K. M., et al. including Jedlowski, P. (2017). Loss of FAM46C Promotes Cell Survival in Myeloma. Cancer Research, 77(23), 6660–6671. https://doi.org/10.1158/0008-5472.CAN-16-3011

  27. Jedlowski, P. M. (2023). Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System. Dermatology, 239(5), 694–699. https://doi.org/10.1159/000530107

  28. Jedlowski, P., & DuPont, J. (2023). Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Journal of Cutaneous Medicine and Surgery, 27(5), 450–456. https://doi.org/10.1177/12034754231182442

  29. Jedlowski, P., & Jedlowski, M. (2023). Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study. Journal of the American Academy of Dermatology, 89(2), 350–352. https://doi.org/10.1016/j.jaad.2023.03.057

  30. Godfrey, H., Jedlowski, P., & Thiede, R. (2024). Medication Associations With Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System. Journal of Cutaneous Medicine and Surgery, 28(1), 51–58. https://doi.org/10.1177/12034754231220931

  31. Leibovit-Reiben, Z., Godfrey, H., Jedlowski, P., & Thiede, R. (2024). Neurologic adverse events associated with BRAF and MEK inhibitor combination therapy: A disproportionality analysis using the FDA Adverse Events Reporting System (FAERS). Journal of the American Academy of Dermatology, 91(3), 560–562. https://doi.org/10.1016/j.jaad.2024.05.048

  32. Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., & Thiede, R. (2024). Erythema multiforme associated with the immune checkpoint inhibitors: A disproportionality analysis using the FDA Adverse Event Reporting System. Journal of the American Academy of Dermatology, 91(4), 785–788. https://doi.org/10.1016/j.jaad.2024.06.012

  33. Leibovit-Reiben, Z., Godfrey, H., Jedlowski, P., & Thiede, R. (2024). TNF-α, IL-1, and JAK Inhibitors Associated with Increased Reporting Odds of Coccidioidomycosis: A Pharmacovigilance Study of FDA Adverse Event Reporting System. Journal of the American Academy of Dermatology, 91(5), 980–983. https://doi.org/10.1016/j.jaad.2024.07.039

  34. Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., & Thiede, R. (2024). Use of fractionated laser therapy for the treatment of androgenetic alopecia: a systematic review and meta-analysis. Lasers in Medical Science, 39, Article 150. https://doi.org/10.1007/s10103-024-04098-w

  35. Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., & Thiede, R. (2025). Effect of Increasing Fluence of Low-Level Laser Therapy for Treatment of Androgenetic Alopecia - a Double-Blinded Randomized Sham-Controlled Trial. Journal of the American Academy of Dermatology, 93(1), 120–123. https://doi.org/10.1016/j.jaad.2025.01.025